Tillett WS, Francis T, Jr.: Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J Exp Med 1930;52:561–571.
Thompson D, Pepys MB, Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169–177.
Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, et al.: Three dimensional structure of human C-reactive protein. Nature Struct Biol 1996;3:346–354.
Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E: Characteriation of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739–743.
5.Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE: Topology and structure of the Clq-binding site on C-reactive protein. J Immunol 2001;166:3998–4004.
Agrawal A, Volanakis JE: Probing the Clq-binding site on human C-reactive protein by site-directed mutagenesis J Immunol 1994;152:5404–5410.
Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW: C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 1995;155:2185–2193.
Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, et al.: The crystal structure of the globular head of complement protein Clq provides a basis for its versatile recognition properties. J Biol Chem 2003;278:46974–46982.
Hurlimann J, Thorbecke GJ, Hochwald GM: The liver as the site of C-reactive protein formation. J Exp Med 1966;123:365–378.
Weinhold B, Rüther U: Interleukin-6-dependent and independent regulation of the human C-reactive protein gene. Biochem J 1997;327:425–429.
Mackiewicz A, Speroff T, Ganapathi MK, Kushner I: Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032–3037.
Li S-P, Liu T-Y, Goldman ND: cis-Acting elements responsible for interleukin-6 inducible C-reactive protein expression. J Biol Chem 1990;265:4136–4142.
Macintyre S, Samols D, Dailey P: Two carboxylesterases bind C-reactive protein within the endoplasmic reticulum and regulate its secretion during the acute phase response. J Biol Chem 1994;269:24496–24503.
Macintyre SS, Kushner I, Samols D: Secretion of C-reactive protein becomes more efficient during the course of the acute phase response. J Biol Chem 1985;260:4169–4173.
Kushner I, Broder MI, Karp D: Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978;61:235.
Pepys MB, Lanham JG, De Beer FC: C-reactive protein in SLE. Clin Rheum Dis 1982;8:91–103.
Martin MFR, Dieppe PA, whicher J, Bell AM: Defective acute phase responses in scleroderma. Ann Rheum Dis 1988;194.
Becker GJ, Waldburger M, Hughes GR, Pepys MB: Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980;39:50–52.
Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, Matsui A: C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol 2001;55:365–370.
Baidoshvili A, Nijmeijer R, Lagrand WK, Hack CE, Niessen HW: Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Path 2002;55:152–153.
Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE: Identification of IgG subclasses and C-reactive protein in lupus nephritis: The relationship between the composition of immune deposits and Fc gamma receptor type IIA alleles. Arthritis Rheum 2003;48:460–470.
Kushner I, Rakita L, Kaplan MH: Studies of acutephase protein. II. Localization of Cxreactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest 1963;42:286–292.
Gitlin JD, Gitlin JI, Gitlin D: Localization of C-reactive protein in synovium of patients with rheumatoid arthritis. Arthritis Rheum 1977;20:1491–1499.
Du Clos TW, Mold C, Paterson PY, Alroy J, Gewurz H: Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol 1981;43:565–573.
Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, et al.: Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137–147.
Parish WE: Studies on vasculitis. I. Immunoglobulins, 1C, C-reactive protein, and bacterial antigens in cutaneous vasculitis lesions. Clin Allergy 1971;1:97–109.
Kushner I, Kaplan MH: Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits: association with necrosis in inflammatory lesions. J Exp Med 1961;114:961–973.
Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14–19.
Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M, et al.: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002;53:1029–1034.
Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88:255–259.
Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K, Duff GW: C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 2002;17:171–174.
Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW: C-reactive protein binding to FcγRIIa on human monocytes and neutrophils is allele specific. J Clin Invest 2000;105:369–376.
Weiser JN, Pan N, McGowan KL, Musher D, Martin A, Richards J: Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998;187:631–640.
Narkates AJ, Volanakis JE: C-reactive protein binding specificities: artificial and natural phospholipid bilayers. Ann NY Acad Sci 1982;389:172–181.
Li YP, Mold C, Du Clos TW: Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol 1994;152:2995–3005.
Vigo C: Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem 1985;260:3418–3422.
Kilpatrick JM, Virella G: Inhibition of platelet activating factor by rabbit C-reactive protein. Clin Immunol Immunopathol 1985;37:276–281.
Filep JG, Herman F, Kelemen E, Foldes-Filep E: C-reactive protein inhibits binding of platelet-activating factor to human platelets. Thrombosis Res 1991;61:411–421.
Du Clos TW: The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1997;23:253–260.
Robey FA, Jones KD, Tanaka T, Liu T-Y: Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem 1984;259:7311–7316.
Du Clos TW: C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol 1989; 143:2553–2559.
Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG: Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994;97:152–157.
Du Clos TW, Zlock L, Marnell LL: Definition of a C-reactive protein binding determinant on histones. J Biol Chem 1991;266:2167–2171.
Jewell WS, Marnell LL, Rokeach LA, Du Clos TW: C-reactive protein binding to the Sm-D protein of snRNPs. Identification of a short polypeptide binding region. Mol Immunol 1993;30:701–708.
Riemekasten M, Trebeljahr K, Hausdorf H, Burmester H: A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998;102:754–763.
Riemekasten G, Kawald A, Weiss C, Meine A, Marell J, Klein R, et al.: Strong acceleration of murine lupus by injection of the SmD183-119 peptide. Arthritis Rheum 2001;44:2435–2445.
Kim SJ, Gershov D, Ma X, Brot N, Elkon KB: Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann NY Acad Sci 2003;987:68–78.
Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW: C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med 1981;154:1703–1708.
Mortensen RF, Osmand AP, Lint TF, Gewurz H: Interaction of C-reactive protein with lymphocytes and monocytes: Complement-dependent adherence and phagocytosis. J Immunol 1976;117:774–781.
Nakayama S, Mold C, Gewurz H, Du Clos TW: Opsonic properties of C-reactive protein in vivo. J Immunol 1982; 128:2435–2438.
Mold C, Rodic-Polic B, Du Clos TW: Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol 2002;168:6375–6381.
Szalai AJ: The antimicrobial activity of C-reactive protein. Microbes Infect 2002;4:201–205.
Berman S, Gewurz H, Mold C: Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol 1986;136:1354–1359.
Mold C, Gewurz H, Du Clos TW: Regulation of complement by C-reactive protein. Immunopharm 1999; 42:23–30.
Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, et al.: A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 2003;33:962–969.
Wolbink GJ, Brouwer MV, Buysmann S, ten Berge IJM, Hack EC: CRP-mediated activation of complement in vivo. J Immunol 1996;157:473–479.
Lagrand WK, Niessen HWM, Wolbink G-J, Jaspars LH, Visser CA, Verheugt FWA, et al.: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97–103.
Ganrot PO, Kindmark C-O. C-reactive protein—a phagocytosis-promoting factor. Scand J Lab Clin Invest 1969;24:215–219.
Mortensen RF, Duszkiewicz JA: Mediation of CRP-dependent phagocytosis through mouse macrophage Fc-receptors. J Immunol 1977;119:1611–1616.
Kilpatrick JM, Volanakis JE: Opsonic properties of C-reactive protein. Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein-coated cells. J Immunol 1985;134:3364–3370.
Nakagomi A, Freedman SB, Geczy CL: Interferongamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000;101:1785–1791.
Pue CA, Mortensen RF, Marsh CB, Pope HA, Wewers MD: Acute phase levels of C-reactive protein enhance IL-1b and IL-1ra production by human blood monocytes but inhibit IL-1b and IL-1ra production by alveolar macrophages. J Immunol 1996;156:1594–1600.
Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW: Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of Interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J Exp Med 1993;178:1629–1636.
Zeller JM, Kubak BM, Gewurz H: Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunol 1989;67:51–55.
Muller H, Fehr J: Binding of C-reactive protein to human polymorphonuclear leukocytes: evidence for association of binding sites with Fc receptors. J Immunol 1986;136:2202–2207.
Zeller JM, Landay AL, Lint TF, Gewurz H: Enhancement of human peripheral blood monocyte burst activity by aggregated C-reactive protein. J Leuk Biol 1986;40:769.
Cosio G, Douglas SD, Michael AF: The human FcR: effects of pronase on soluble immune complex binding by polymorphonuclear leucocytes, monocytes and pulmonary macrophages. Immunol 1982;46:395–400.
Debets JMH, van de Winkel JGJ, Ceuppens JL, Dieteren IEM, Buurman WA: Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions: functional activation of Fc gamma RII by treatment with proteases or neuraminidase. J Immunol 1990;144:1304–1310.
van de Winkel JGJ, van Ommen R, Huizinga TWJ, de Raad MAHVM, Tuijnman WB, Groenen PJTA, et al.: Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG. J Immunol 1989;143:571–578.
Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C: C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to FcγRI. J Immunol 1991;147:3445–3451.
Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, Raynes JG: C-reactive proteinmediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunol 2002;107:252–260.
Szabo G, Miller-Graziano CL, Wu JY, Takayama T, Kodys K: Differential tumor necrosis factor production by human monocyte subsets. J Leuk Biol 1990; 47:206–216.
Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW: The major receptor for C-reactive protein on leukocytes is FcγRII. J Exp Med 1999;190:585–590.
Bharadwaj D, Mold C, Markham E, Du Clos TW: Serum amyloid P component binds to Fcgamma receptors and opsonizes particles for phagocytosis. J Immunol 2001;166:6735–6741.
Chi M, Tridandapani S, Zhong W, Coggeshall KM, Mortensen RF: C-reactive protein induces signaling through Fc gamma RIIa on HL-60 granulocytes. J Immunol 2002;168:1413–1418.
Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte FcgammaRI expression and improved Fcgamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997;90:3187–3194.
Ballou SP, Lozanski G: Induction of inflammatory cytokine release from human monocytes by C-reactive protein. Cytokine 1992;4:361–368.
Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, Dayer JM: C-reactive protein increases production of IL-l alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. J Leuk Biol 1993;53:439–445.
Arend WP, Smith MF, Janson RW, Joslin FG: IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 1991;147:1530–1536.
Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW: C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002;169:7019–7025.
Stein MP, Mold C, Du Clos TW: C-reactive protein binding to murine leukocytes requires Fcγ receptors. J Immunol 2000;164:1514–1520.
Sylvestre DL, Ravetch JV: A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 1996;5:387–390.
Mold C, Gresham HD, Du Clos TW: Serum amyloid P component (SAP) and C-reactive protein (CRP) mediate phagocytosis through murine Fcγ receptors. J Immunol 2001;166:1200–1205.
Sutterwala FS, Noel GJ, Salgame P, Mosser DM: Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. J Exp Med 1998;188:217–222.
Ravetch JV, Lanier LL: Immune inhibitory receptors. Science 2000;290:84–89.
Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV: Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1995;379:346–349.
Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV: Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999;189:179–185.
Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH, Jr.: Human C-reactive protein is protective against fatal Salmonella enterica Serovar Typhimurium infection in transgenic mice. Infect Immun 2000;68:5652–5656.
Colina J, Shen Y, Snapper CM: Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein-and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms. J Exp Med 2002;195:1–13.
Szalai AJ, Briles DE, Volanakis JE: Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995;155:2557–2563.
Lysenko E, Richards JC, Cox AD, Stewart A, Martin A, Kapoor M, Weiser JN: The position of phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae affects binding and sensitivity to C-reactive protein mediated killing. Mol Immunol 2000;35:234–235.
Szalai AJ, Briles DE, Volanakis JE: Role of complement in C-reactive protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun 1996;64:4850–4853.
Saeland E, Vidarsson G, Leusen JH, Van Garderen E, Nahm MH, Vile-Weekhout H, et al.: Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol 2003;170:6158–6164.
Xia D, Samols D: Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci USA 1997;94:2575–2580.
Chae MR, Park BH, Kim JS, Rho JW, Kim HR: Protective effect of C-reactive protein against the lethality induced by Vibrio vulnificus lipopolysaccharide. Microbiol Immunol 2000;44:335–340.
Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB: Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad USA 2000;97:14584–14589.
Heuertz RM, Samols D, Webster RO: Transgenic mice expressing plasma rabbit C-reactive protein exhibit diminished vascular permeability and neutrophil infiltration in C5a-induced alveolitis. FASEB J 1994;8:A1064.
Heuertz RM, Dongyuan X, Samols D, Webster RO: Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am J Physiol 1994;266:L649-L654.
Kew RM, Hyers TM, Webster RO: Human C-reactive protein inhibits neutrophil chemotaxis in vitro: Possible implications for the adult respiratory distress syndrome. J Lab Clin Med 1990;115:339–345.
Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of Tumor Necrosis Factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547–550.
Du Clos TW, Zlock L, Hicks PS, Mold C: Decreased autoantibody levels and enhanced survival of (NZB X NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopath 1994;70:22–27.
Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF, et al.: Delayed lupus onset in (NZBxNZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003;48:1602–1611.
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–742.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
Ridker P, Buring J, Shih J, Matiaws M, Hennekens C: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731–733.
Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sahail M, Drausz T, Pepys MB: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733–1739.
Nagpurkar A, Mookerjea S: A novel phosphorylcholine-binding protein from rat serum and its effect on heparin-lipoprotein complex formation in the presence of calcium. J Biol Chem 1981;256:7440–7446.
Diaz Padilla N, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE: Rat C-reactive protein activates the autologous complement system. Immunol 2003;109:564–571.
Cermak J, Key N, Bach R, Balla J, Jacob H, Vercellotti G: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513–520.
Zhou P, Thomassen MJ, Pettay J, Deodhar SD, Barna BP: Human monocytes produce monocyte chemoattractant protein 1 (MCP-1) in response to a synthetic peptide derived from C-reactive protein. Clin Immunol Immunopathol 1995;74:84–88.
Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–2534.
Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, et al.: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Circulation 2003;108:512–515.
Rodriguez W, Mold C, Katavanovski M, Hutt J, Marnell LL, DuClos TW: C-reactive protein reverses on going proteinuria in autoimmune mice. Arthritis Rheum 2004; in press.